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ABSTRACT
We previously reported that autocrine TNF-α (TNF) is responsible for JNK
pathway activation in a subset of acute myeloid leukemia (AML) patient samples,
providing a survival/proliferation signaling parallel to NF-κB in AML stem cells (LSCs).
In this study, we report that most TNF-expressing AML cells (LCs) also express
another pro-inflammatory cytokine, IL1β, which acts in a parallel manner. TNF was
produced primarily by LSCs and leukemic progenitors (LPs), whereas IL1β was mainly
produced by partially differentiated leukemic blasts (LBs). IL1β also stimulates an
NF-κB-independent pro-survival and proliferation signal through activation of the JNK
pathway. We determined that co-inhibition of signaling stimulated by both TNF and
IL1β synergizes with NF-κB inhibition in eliminating LSCs both ex vivo and in vivo.
Our studies show that such treatments are most effective in M4/5 subtypes of AML.

under 60 years of age, and <10% for patients 60 years of
age and older [1–4]. In addition, intensive chemotherapy
is limited in older patients due to life-threatening
inflammation-mediated complications and side effects
[5, 6]. Therefore, the development of more specific and
efficient targeting strategies for eliminating LSCs in AML
treatment is urgent.
NF-κB is a key transcriptional regulator of
inflammatory cytokine-stimulated signaling and plays
a central role in the development and progression of
inflammation-associated cancer [7–10]. NF-κB is also
required for maintenance of LSCs. In AML, tumor necrosis
factor-α (TNF hereafter) and NF-κB promote LSC survival
and proliferation in a feed-forward manner [11]. While
NF-κB activity is undetectable in unstimulated normal
CD34+ hematopoietic stem/progenitor cells (HSPCs), it

INTRODUCTION
Acute myeloid leukemia (AML) is a common
hematopoietic malignancy in adults. Incidence is
increased in aged populations with average age of 67
years at diagnosis. Intensive chemotherapy is the standard
treatment for AML (except for M3 subtype), which
can induce complete remission in 40-70% of patients.
However, such treatment cannot eliminate AML stem
cells (LSCs) in almost all cases, and the remaining
LSCs, described as minimal residual diseases (MRD),
can reconstitute the tumor by producing new leukemic
progenitors (LPs) and leukemic blasts (LBs). Thus, almost
all AML patients will succumb to disease relapse due to
drug-resistant LSCs and their progeny. Currently, 5-year
overall survival for AML patients is 40 to 45% for patients
www.impactjournals.com/oncotarget
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Tnfr-/- LCs (genomic deletion of Tnfr1/2) into sub-lethally
irradiated mice and treating with NF-κB inhibitor –
(Figure 1D-1F). Consistent with the results of our previous
study [16], mice which had received Tnfr-/- LCs required
longer latency for leukemia development than mice which
had received WT LCs (Supplementary Figure 1). We
found that, compared to the vehicle-treated group, NFκB inhibition was able to slightly extend the lifespan of
mice which had received Tnfr-/- LCs, while a combination
of JNK or NF-κB inhibitors also significantly reduced the
tumor burden and prolonged the life of Tnfr-/- leukemic
mice (Figure 1D–1F). These data suggested that in
addition to TNF, other cytokine(s) might also protect LCs
from NF-κB inhibition in vivo by stimulating JNK.

is constitutively activated in CD34+CD38- LSCs isolated
from almost all AML patients [12–14]. Also, inactivation
of NF-κB signaling selectively eradicates LSCs in vitro
especially when combined with chemotherapeutic drugs
without significant influence on the survival and growth
of normal HSPCs [15]. This suggests that targeting NF-κB
could be an effective treatment paradigm for eliminating
LSCs. However, the anti-leukemia effects of NF-κB
inhibition in clinical patients are inadequate, suggesting
a protective mechanism exists within the bone marrow
environment.
We reported that in many subtypes of AML,
especially in M4 and M5, the anti-leukemia effects of NFκB inhibition are attenuated by autocrine TNF stimulation
of JNK (a survival/proliferation signal in LCs) and
paracrine TNF stimulates a JNK-mediated necroptotic/
apoptotic signal in HSPCs [16]. We determined that
inhibition of TNF-JNK signaling provided improved
treatment for TNF-expressing AML when combined with
NF-κB inhibitors. We also found that co-inhibition of
JNK and NF-κB signaling was also effective in some TNF
non-expressing LCs and patient samples, suggesting that
other cytokines might be secreted by LCs which can also
activate JNK signaling in addition to TNF [16].
In this study, we found that in addition to TNF, most
LCs, especially M4 and M5 LCs, also secrete interleukin
1β (IL1β). IL1β stimulation of both NF-κB and JNK
signaling protects LSCs and LPs from NF-κB inhibition
by compensating TNF signaling. Our study suggests that
inhibition of both TNF and IL1β signaling could represent
an improved treatment for inflammatory cytokinesecreting AML when combined with an NF-κB inhibitor.

The sensitivity of LSCs and LPs to NF-κB
inhibition in culture was dependent on cell
density
Using purified LSCs, which are normally cultured in
in vitro studies at a relatively low density, previous studies
demonstrated that LSCs are highly sensitive to NF-κB
inhibitor treatment [12, 13]. In our previous studies, we
also cultured LCs at a relatively low density (1-2×105/
ml). To examine the responses of LSCs and LPs to NF-κB
inhibition, we used an unpurified mixed population of LCs
containing LSCs, LPs and partially differentiated LBs in
our studies because we believed that such a mixture of
cells would be more representative of the real situation
of LCs in patient bone marrow tissues. MA9-transduced
murine LCs were used as a model system in our studies
because LPs and LSCs among such LCs can be reliably
evaluated by colony-forming unit (CFU) assay and in vivo
transplantation assay, respectively [16, 18].
To test whether cell density influences the response
of LCs to NF-κB inhibition, we incubated LCs at indicated
densities with or without 100nM BAY for 12 hours. Cells
were then collected and seeded into methylcellulose
for CFU (Supplementary Figure 2). We found that the
sensitivity of LCs to NF-κB inhibitor treatment is dependent
on cell density. We then treated LCs in high density (HD,
5×105/ml) and low density (LD, 1×104/ml) conditions with
indicated dosages of BAY for 12 hours. Cells were then
collected for CFU (Figure 2A) or injected into lethallyirradiated receipt mice for transplantation studies (Figure
2B). We found that, consistent with previous studies, LPs
(Figure 2A) and LSCs (Figure 2B) are highly sensitive to
BAY treatment in LD culture, as demonstrated by CFU
assay and ex vivo treatment followed by transplantation.
BAY treatment induced significant apoptosis in LCs in the
LD condition, as shown by cell morphology (Figure 2C)
and Annexin-V staining (Figure 2D). Tnfr-/- LCs are more
sensitive to NF-κB inhibitor treatment compared to WT
LCs in such LD conditions (Figure 2E). However, when
cultured in HD conditions, the killing effects of NF-κB
inhibition on LPs (Figures 2A, 2E) and LSCs (Figure 1B)

RESULTS
TNF signaling inactivation only slightly
potentiated the anti-leukemic effects of NF-κB
inhibitor in vivo
We reported that TNF stimulates JNK signaling to
protect LCs from NF-κB inhibition as shown in primary
patient samples, human AML cell lines and MLL-AF9
(MA9)-transduced murine LCs. Inhibition of either TNF
or JNK could significantly increase the sensitivity of LCs
to NF-κB inhibitor treatment in vitro [16]. Consistent with
this observation, we found that combined treatment with
both the NF-κB inhibitor BAY11-7802 (BAY hereafter)
and the JNK inhibitor SP600125 (SP hereafter) profoundly
reduced the tumor burden and prolonged the survival of
leukemic mice developed from MA9 transduction (Figure
1A-1C). Currently, there are no clinically available JNK
inhibitors approved for use in human subjects; however
many TNF blockers have been developed for the clinical
treatment of inflammatory diseases such as arthritis [17].
Therefore, we tested whether inhibition of TNF can also
sensitize LCs to NF-κB inhibition in vivo by transplanting
www.impactjournals.com/oncotarget
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were significantly attenuated in both WT and Tnfr-/- LCs.
However, the sensitivity of LPs to the NF-κB inhibitor
could be largely restored by JNK inhibition (Figure 2E and
Supplementary Figure 3), further supporting the notion that,
in addition to TNF, other factors secreted by LCs might
also provide protection to LPs and LSCs [16, 19] through
activation of JNK. To further support this notion, we found
that JNK signaling was more highly activated in WT LCs
than in Tnfr-/- LCs when cultured in LD condition. However,
in HD culture, JNK signaling was comparable between WT
and Tnfr-/- LCs (Figure 2F).

of NF-κB inhibitors, we first analyzed the expression
profile of inflammatory cytokines in 580 primary human
AML samples in our microarray data (Figure 3A).
Although the expression levels of TNF are generally
elevated in M3/4/5AML cells compared to normal
HSPCs, a subset of M4 and M5 AML samples also express
much higher levels of IL1 (both α and β). We confirmed
in newly-diagnosed M4/5 subtype AML patients that
there were increased levels of pro-inflammatory
cytokines TNF and IL-1 in their peripheral blood (Figure
3B), which correlated to the increased TNF and IL1
expression by CD34+ tumor cells (Figure 3B). We also
determined that MA9-transduced murine LCs expressed
and produced endogenous TNF and IL1β (Figure 3D).
Consistent with a previous study [11], we found that TNF
is highly expressed in c-kit+ LSCs and LPs (Figure 3E).
In addition, we found that IL1β is highly expressed in

IL1 promoted the growth of LPs independent of
TNF
To search for these other autocrine factors that can
activate JNK targets and counteract the anti-AML effects

Figure 1: Inactivation of TNF failed to sensitize LCs to NF-κB inhibition in vivo. WT LCs A-C. and Tnfr-/- LCs D-F. were

transplanted into sub-lethally irradiated mice. Schematic diagram of the experimental procedures (A, D). On day 15 post-transplantation,
mice were randomly divided into four groups and were treated with vehicle, 30 mg/kg SP6 or 10mg/kg BAY individually or in combination
daily for 10 days. Livers were collected from recipient mice on day 30 post-transplantation for WT LCs (B-C) and on day 40 posttransplantation for Tnfr-/- LCs (E-F). Three mice from each group were analyzed. Infiltration of LCs was examined by H & E staining
of liver sections. The ratio of liver/body weight was presented. Bars, 200μM. Survival of the recipient mice was analyzed by KaplanMeier survival graphing (A, D). Numbers of mice used in each group were noted. Leukemia was confirmed at the time of death of
each transplanted mouse. * indicates p<0.05 when compared to vehicle-treated control. # indicates p<0.05 when compared to Bay or SP
individual inhibitor-treated groups.
www.impactjournals.com/oncotarget
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c-kitlow/- partially-differentiated LBs compared to c-kit+
LSCs/LPs (Figure 3E). In human primary LCs, TNF was
highly expressed in CD34+ LSCs and LPs, while IL1β was
highly expressed in CD34- LBs (Figure 3F). Significantly
higher concentrations of IL1β were detected in LC culture
medium when cultured in HD conditions than when
cultured in LD conditions (Figure 3G).
We found that IL1β can induce JNK signaling
independent of TNF signaling (Figure 4A). To
study whether IL1β can promote the growth of LCs
independently of TNF, we treated MA9-transduced
Tnfr-/- LCs and MA9-transduced Tnfr wild-type LCs (WT
LCs hereafter) with IL-1β and measured proliferation
and colony formation. We observed that IL1β promotes
proliferation (Figure 4B) and colony-forming ability
in both Tnfr-/- and WT LCs in a dose-dependent fashion
when <50ng/ml of IL1β was used (Figure 4C). IL-1
doses >50 ng/mL did not further enhance CFUs in LCs.
Although IL1β also promotes the clone-forming capacity
of HSPCs (Figure 4D), we found that it compromises
the hematopoietic reconstitutive ability of hematopoietic
stem cells (HSCs) as demonstrated by ex vivo treatment
and transplantation studies (Figure 4E). This suggests that

although IL1β promotes the colony-forming ability of
normal progenitors, it represses HSC function. We then
treated the LCs with a combination of IL1RA, a natural
IL1 antagonist, and anti-TNF, a TNF neutralizing antibody.
We found that the combined inhibition of IL1β and TNF
signaling had an additive, dose-dependent repressive effect
on CFU in LCs (Figure 4F). We confirmed this conclusion
by treating Tnfr-/- LCs with IL1RA (Figure 4G). To verify
the specificity of IL1RA treatment, we knocked down
IL1 receptor-1 (IL1R) in LCs by shRNA (Figure 4H).
We found that genetic inhibition of IL1R also sensitized
LCs to anti-TNF treatment (Figure 4I). LCs with IL1R
knockdown generated far fewer CFUs in the presence of
anti-TNF when compared to Scr-shRNA-transduced LCs.

Combined inhibition of TNF and IL1 sensitized
LPs and LSCs to NF-κB inhibition in highdensity culture condition
Since both TNF and IL-1 stimulate the activation
of JNK [16] (Figure 4A), we treated WT LCs in HD
condition with IL1RA or anti-TNF individually or in
combination for CFU assay in the presence or absence

Figure 2: Inactivation of TNF failed to sensitize LSCs and LPs to NF-κB inhibition in vitro when cultured at high
density. WT LCs were cultured at low density (1×104/ml, LD) or high density (5×105/ml, HD) and treated with indicated concentrations

of BAY for 12 hours. Cells were collected for colony-forming assay, A. transplanted into recipient mice for leukemia development B., cell
morphology (the numbers presented in each photo are the percentage of morphologically apoptotic cells) C., or cell death by AnnexinV/7AAD staining D. The numbers of cells seeded per plate or transplanted per mouse were based on the number of initial treated cells.
Results shown are indicative of three independent trials in (A). Five mice were used in each treatment group in (B). ** indicates p<0.01
when compared to vehicle controls. ## indicates p<0.01 when compared to HD groups with the same dosage of BAY. E. WT and Tnfr-/- LCs
were incubated at LD (1×104/ml) or HD (5×105/ml) and were treated with 200nM Bay, 10μM SP6 or both in combination for 12 hours and
then collected for CFU assay. Vehicle-treated cells were used as controls. * indicates p<0.05 when compared to vehicle-treated controls.
$ indicates p<0.05 when compared to WT LCs. # indicates p<0.05 when compared to HD groups with same treatments. & indicates p<0.05
when compared to HD groups with Bay or SP individual treatment. F. WT (lanes 1 and 3) and Tnfr-/- LCs (lanes 2 and 4) were incubated at
LD (1×104/ml) or HD (5×105/ml) for 24 hours. JNK and NF-κB signaling activity were compared by Western blotting.
www.impactjournals.com/oncotarget
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Figure 3: Expression of both TNF and IL1β in many types of LCs. A. Expression of TNF, TNFR, IL-1, IL-1R, c-JUN and JUNB

in primary human AML samples was compared by microarray. B. TNF and IL-1 protein levels in PB of AML patients were examined by
ELISA. C. TNF and IL-1 mRNA in primary AML samples were examined by qRT-PCR assay. D. Schematic for development of murine
MA9- and Runx1-Eto-9a LCs. TNF and IL1β expression was examined by Western blotting. Each lane was from LCs from a separate
transplanted mouse. E. Expression of TNF and IL1β in c-kit+ LSCs/LPs and c-kitlow/- LBs isolated from murine MA9-LCs were examined
by qRT-PCR. F. Expression of TNF and IL1β in CD34+ LSCs/LPs and CD34low/- LBs isolated from 4 primary AML patient samples was
examined by qRT-PCR. G. MA9-LCs were cultured in LD or HD conditions. IL1β concentration was examined in the culture medium at
indicated times of incubation.
www.impactjournals.com/oncotarget
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Figure 4: IL-1 promotes the growth of clonogenic LPs. A. WT, Tnfr-/-, Rip1-/- LCs were treated with IL1β for 15 minutes. JNK

activity was examined by Western blotting. B. WT LCs and Tnfr-/- LCs cultured in LD condition (1×104/ml) and treated with 50ng/ml of
IL1β. Twelve hours after treatment, cells were treated with 10μM BrdU for an additional 2 hours. Cells were collected for BrdU staining
using APC BrdU Flow Kits (BD Pharmingen) following the protocol provided by the vender. * indicates p<0.05 compared to untreated
WT LCs. # indicates p<0.05 compared to untreated controls. C. WT and Tnfr-/- LCs were cultured in LD condition (1×104/ml) and treated
with increasing concentrations of recombinant IL-1β for 12 hours. Cells were then were seeded for CFU assay. D. Normal bone marrow
mononuclear cells (MNCs) were treated with increasing concentrations of IL1β for 12 hours and then seeded for CFU assay. E. One million
bone marrow MNCs were isolated from normal CD45.1+ mice and treated with indicated concentrations of IL-1β for 24 hours. Treated
cells were mixed with 1×106 support MNCs (CD45.2+) and transplanted into lethally-irradiated recipient mice (CD45.2+) to evaluate
hematopoietic reconstitutive capacity. Five mice were used in each treatment group. F. WT LCs were cultured in HD condition (5×105/ml)
and treated with 20ug/ml of anti-TNF and indicated doses of IL-1RA for 12 hours. Cells were collected and seeded for CFU. G. WT and
Tnfr-/- LCs were cultured in HD condition and treated with increasing concentrations of IL-1RA for 12 hours. Cells were collected for CFU
assay. H. shRNA knockdown of IL-1 receptor 1 (IL-1R1) in LCs as determined by qRT-PCR. I. LCs transduced with shRNAs specific for
IL-1R (sh-IL-1R-1 and sh-IL-1R-2) were cultured in HD condition and treated with or without 20ug/ml of anti-TNF. Twelve hours hence,
cells were seeded for CFU assay. Scrambled (Scr)-shRNA transductions were studied in parallel as controls. * indicates p<0.05 when
compared to 0ng/ml IL1β group (C-E), or 0ng/ml IL1RA groups (F, G), or Scr groups (H, I). # indicates p<0.05 when compared to WT
LCs (C, G), and vehicle groups (F, I) as determined by one-way ANOVA.
www.impactjournals.com/oncotarget
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of the NF-κB inhibitor BAY for 12 hours and seeded
them for CFU. We found that while IL1RA or anti-TNF
alone can repress the CFU of LCs, combination treatment
significantly enhances the CFU inhibitory activity of the
NF-κB inhibitor, suggesting that co-inactivation of IL1
and TNF signaling can significantly sensitize LCs to NFκB inhibition in HD culture condition (Figure 5A). We
confirmed this conclusion by treating Tnfr-/- LCs with
IL1RA and BAY alone or in combination (Figure 5B).

We also further confirmed the conclusion by treating
IL1R-knockdown LCs with anti-TNF and BAY alone
or in combination (Figure 5C). However, inhibition of
both TNF and IL-1R signaling did not enhance the CFU
inhibitory activity of the JNK inhibitor, suggesting that
TNF and IL-1 are the primary stimuli for JNK in LCs
(Supplementary Figure 4).
We then determined that treatment of LCs with
IL1RA, anti-TNF, or BAY alone or in the indicated

Figure 5: LSCs and LPs with both TNF and IL-1 signaling inactivation are much more sensitive to NF-κB inhibition
than are LSCs and LPs with inactivation either of the cytokine signaling alone. A. WT LCs were cultured in HD condition

(5×105/ml) and treated with 20ug/ml of anti-Tnf, 500ng/ml IL-1RA, 150nM BAY individually or in combination for 12 hours, and then
seeded into methylcellulose for CFU assay. Vehicle treatment was used as a control. B. WT LCs and Tnfr-/- LCs in HD condition were
treated with 500ng/ml IL-1RA and 100nM of BAY individually or in combination for 12 hours and seeded for CFU assay. C. sh-IL-1R1-transduced LCs (as described in Figure 4G) cultured in HD condition were treated with 100nM BAY or anti-TNF for 12 hours and
then seeded for CFU assay. Scrambled shRNA (Scr) transductions were studied in parallel as controls. D. WT LCs were cultured in HD
condition (5×105/ml) and treated with 20ug/ml of anti-Tnf, 500ng/ml IL-1RA, 100nM BAY individually or in indicated combinations for
12 hours. Cells were collected and transplanted to assess leukemogenic ability. Vehicle treatment was used as a control. E. Tnfr-/- LCs were
cultured in in HD condition (5×105/ml) and treated with 500ng/ml IL-1RA or 100nM BAY individually or in combination for 12 hours.
Cells were collected and transplanted to assess leukemogenic ability. Two thousand initial cells were transplanted into lethally-irradiated
recipient mice with BM support cells. Survival of the recipient mice was analyzed by Kaplan-Meier survival graphing. Results shown
for (A-C) are representative of three independent trials. * indicates p<0.05 when compared to vehicle control; # indicates p<0.05 when
compared to individual chemical treatment groups; & indicates p<0.05 when compared to two chemical combination groups. Statistical
significance was determined by one-way ANOVA with Bonferonni post-hoc test.
www.impactjournals.com/oncotarget
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combinations ex vivo had effects specific to LSCs by
performing ex vivo treatment followed by transplantation.
After 24 hours of indicated treatments, LCs were
collected for cell death analysis and transplanted into
recipient mice to observe for leukemia development
(Figure 5D). Each mouse was transplanted with 2×103
of the initial LCs. Mice were then observed for leukemia
development. A significant increase in cell death was
detected in IL1RA, anti-TNF, or BAY single-treated
LCs when compared to vehicle treated control; cell
death was further increased in any of the two drug
combination groups and even further increased in the
three drug combination condition (Supplementary Figure
5a). As a consequence, we found that disease onset in
mice that had received either IL1RA, anti-TNF, or BAY
single-treated LCs was significantly delayed compared
to mice receiving vehicle-treated LCs, and was even
further delayed in mice receiving LCs treated with any
of these two chemical combinations. Most importantly,
mice receiving all three chemically-treated LCs survived
longest, with 3 out of 8 mice surviving over 135 days
without any sign of leukemia (Figure 5D). This study
suggested that co-inhibition of TNF and IL-1 signaling
significantly enhanced the ability of NF-κB inhibitor to
eliminate LSCs. We confirmed these results by combined
treatment of Tnfr-/- LCs with IL1Ra and BAY ex vivo
(Figure 5E). IL1RA or BAY treatment induced significant
cell death in Tnfr-/- LCs. Significantly more cell death
was detected in the IL1RA and BAY combination
group (Supplementary Figure 5b). Consistent with this
observation, mice receiving BAY or IL1RA-treated Tnfr-/LCs required a significantly longer latency for leukemia
development than mice receiving vehicle-treated Tnfr-/LCs. Mice which had received BAY plus IL1RA treated
Tnfr-/- LCs survived much longer, with 5 out of 8 mice
surviving over 135 days without any sign of leukemia.
Taking together, our data suggest that inactivation
of both IL1 and TNF signaling is more effective in
facilitating NF-κB inhibitor-mediated LSC elimination
than inactivation of either alone (Figure 5E).

(Figure 6A). We confirmed these results by combined
treatment of Tnfr-/- LCs with IL1RA and BAY (Figures
6D-6F). In vivo treatment demonstrated that mice
which had received Tnfr-/- LCs survived significantly
longer after treatment with BAY and IL1RA in
combination than mice treated with either BAY or
IL1RA individually (Figure 6D) due to the much more
significant repression of disease progression as shown
by reduced liver infiltration of LCs (Figure 6C, 6D).
Taken together, our data suggest that inactivation
of both IL1β and TNF signaling is more effective in
facilitating NF-κB inhibitor-induced repression of
leukemia development. Our data suggested that the
anti-leukemia effect of NF-κB inhibition in vivo can be
significantly enhanced by inhibition of either TNF or
IL1 signaling alone, and can be further promoted by
co-inhibition of both TNF and IL1 signaling (Figure 6).

Inactivation of individual AP1 factors reduced
colony-forming ability and promoted the
sensitivity of LCs to NF-κB inhibition
We have reported that TNF induces necroptosis/
apoptosis in normal HSPCs by stimulating a prolonged
activation of JNK signaling. However, in LCs, the
expression of MKP5 turns off JNK signaling shortly
after its activation. Thus, TNF induces only a transient
JNK activation in LCs [16]. Such transitory activation
of JNK promotes the proliferation and survival of LCs
by activating downstream transcription factors, such as
the AP1 family. Upon stimulation with TNF or IL1β,
c-Jun, JunB and JunD were activated in LCs as shown by
increased phosphorylation of these proteins (Figure 7A).
To determine which AP1 component responds to TNF/
IL1-induced survival and proliferation of LCs, we
transduced LCs with shRNA specific for c-Jun, JunB
and JunD respectively. The knockdown efficiencies
of target genes were examined by Western blotting
(Figure 7B). We then selected the LCs with the most
efficient target gene knockdown for functional studies.
Dominant negative (DN)-AP1 is a mutant form of the
c-Jun gene repressing most of the activity of AP1. The
effect of DN-AP1 was verified by down-regulation of
c-Jun, a well-documented AP1 target gene (Figure 7C).
Using CFU assay, we demonstrated that inactivation of
c-Jun and JunB but not JunD repressed the clonogenic
capacity of LCs (Figure 7D). LCs with either c-Jun
or JunB knockdown showed increased sensitivity to
NB-κB inhibitor treatment compared to Scr-shRNAtransduced control (Figure 7E). DN-AP1 transduction
showed much stronger effects in both repressing
clonogenic capacity and enhancing NF-κB inhibitor
sensitivity than knockdown any of the individual AP1
family members (Figure 7D–7E). Most interestingly,
LSCs and LPs in MA9-leukemia express CD117 and
lose this surface marker during differentiation. We found

Combined inhibition of TNF/IL1 and NF-κB
repressed leukemia development in vivo
To evaluate the anti-leukemia effect of the
combined treatment in vivo, we generated murine
leukemia by transplanting WT LCs into recipient mice.
These mice were treated with the indicated drugs 15
days following transplantation. We found that treatment
with any of the single drugs in our study reduced disease
burden as shown by reduced liver infiltration (Figure
6B, 6C) and prolonged survival by one week (Figure
6A), with any double inhibitor treatment prolonging
survival by another week. Triple inhibition of TNF,
IL1, and NF-κB profoundly reduced the disease burden
and prolonged survival by a maximum of 90 days
www.impactjournals.com/oncotarget
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Combined inhibition of TNF and IL1 potentiated
NF-κB inhibitor in repressing colony growth of
primary human LCs

that DN-AP1-transduced LCs showed a differentiated
phenotype as demonstrated by both cell morphology
and reduced CD117 expression (Figure 7F). Therefore,
we predicted that multiple AP1 family members might
be involved in regulating proliferation, survival and
differentiation of LCs downstream of JNK.

IL1β induces TNF-independent activation of JNK
signaling through the RIP1-MYD88-IRAK pathway

Figure 6: Inhibition of both TNF and IL-1 signaling could more effectively repress leukemia development in vivo
than inactivation of either individual signaling pathway when combined with NF-κB inhibitor. WT LCs A-C. or Tnfr-/LCs D-F. were transplanted into sub-lethally irradiated recipient mice. Fifteen days following transplantation, mice were treated with
100mg/kg IL-1RA, 10 mg/kg anti-TNF, or 10mg/kg BAY individually or in combinations as indicated every day for 10 days. Survival of the
recipient mice was analyzed by Kaplan-Meier survival graphing. Leukemia was confirmed at the time of death for each transplant mouse.
*and ** indicate p<0.05 and p<0.01, respectively, when compared to vehicle-treated control, # indicates p<0.05 when compared to single
or double treatment controls as determined by log-rank test. Livers were collected in a batch of recipient mice on day 28 for WT LCs (B, C)
or day 42 for Tnfr-/- LCs (E, F) of transplantation. LC infiltration was examined by H & E staining of liver sections (B, E) and the ratio of
liver/body weight was analyzed (C, F). In C, 1 stands for Vehicle; 2 for IL1RA; 3 for Anti-TNF; 4 for IL1RA + anti-TNF; 5 for anti-TNF +
BAY; 6 for IL1RA + BAY; 7 for IL1RA + anti-TNF+ BAY. In F, 1 stands for Vehicle; 2 for IL1RA; 3 for BAY; 4 for IL1RA + BAY. Three
mice from each group were analyzed. *and ** indicate p<0.05 and p<0.01, respectively, when compared to vehicle-treated control.
www.impactjournals.com/oncotarget

8428

Oncotarget

[20, 21]. Caspase-1 (CASP1) is the IL1 converting enzyme
(ICE) which is required for IL1β secretion and activity.
CASP1 is highly expressed in the M4 and M5 subtypes
of AML cells (Figure 8A), levels of which are correlated
to poorer patient outcome (Figure 8B) as shown by
analysis of the AGCT database. Increased expression of
IL1RAP and IRAK1 as well as “elevated IRAK1-recruit
IKK complex and Mahajan_response_to_IL1A pathway”
is also associated with poorer prognosis of AML patients,
while the increased expression of IRAK1BP1, a negative

regulator of IRAK1 signaling, is correlated to better
prognosis (Figure 8B).
To determine whether inhibition of both TNF and
IL1 can also promote the anti-leukemic ability of NF-κB
inhibition in primary human AML, we treated primary
human LCs freshly isolated from peripheral blood of AML
patients with BAY and TNF/IL-1 antagonists (Enbrel®
and Kinaret®, respectively) individually or in combination
in methylcellulose for CFU assay. We found that combined
inhibition of NF-κB and TNF/IL1 did not have an additive

Figure 7: IL-1 stimulates the activation of JNK-AP1 signaling in LCs. A. WT LCs were treated with TNF or IL1β for 15

minutes. The activity of JNK signaling was examined by detecting the levels of p-JNK, p-Jun, p-JunB and p-JunD. B. LCs were transduced
with shRNAs specific for c-Jun, JunB or JunD; gene knockdown efficiency was determined by Western blotting. C. The effect of DN-AP1
transduction was verified by qRT-PCR to detect downregulation of c-Jun. D. Clonogenic capacity of gene knockdown LCs was compared
to Scr shRNA-transduced LCs and DN-AP1-transduced LCs by CFU assay. E. The sensitivity of gene knockdown LCs to NF-κB inhibitor
treatment was compared to Scr shRNA-transduced LCs and DN-AP1-transduced LCs by CFU assay. F. The morphology and CD117 surface
expression were compared among the gene knockdown LCs, Scr shRNA-transduced LCs and DN-AP1-transduced LCs after 72 hours
of suspension culture. A, B, C, F are representative of three independent trials. * indicates p<0.05 when compared with Scr-ShRNA or
vector-transduced LCs as determined by one-way ANOVA with Bonferroni’s post-hoc test. # indicates p<0.05 between compared groups
as determined by one-way ANOVA with Bonferroni’s post-hoc test.
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Figure 8: M4/5 AML is highly susceptible to combined TNF/IL-1 and NF-κB inhibition treatment. A. High levels of

expression of Caspase 1 in M4 and M5 subtypes of AML samples as shown by analysis of the TCGA database. B. Correlation of IL1-IRAK
signaling to patient outcome was examined by analyzing the TCGA database. C. Primary AML cells isolated from patient peripheral blood
or bone marrow samples were treated with indicated drugs at indicated doses in methylcellulose for CFU assay. Colonies were read after
14 days. Results were normalized to vehicle-treated control for each patient sample. Each dot represents one patient, n=5 for each group.
Horizontal bars represent mean, vertical bars represent one SD. *** in A indicates p<0.05 when compared to indicated groups; # indicates
p<0.05 when compared to vehicle group; & indicates p<0.05 when compared to other groups.
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repressive effects on CFU in M0/1/2 subtypes of LCs,
but synergized in M4/5 subtypes of LCs as well as LCs
from AML patients secondary to MDS or therapy for other
cancers (Figure 8C).

an anti-AML target [37]. The expression levels of many
other key components of the IL1 signaling pathway are
also increased in AML patient samples, and such increases
indicate a poorer patient prognosis (Figure 8). Thus the IL1
pathway has been described as a critical therapeutic target
for AML. However, despite of the effective repressive
role of IL1 antagonists (such as sIL-R or IL1RA) on the
growth of LCs in in vitro culture [38–40], inhibition of IL1
signaling might not be able to successfully repress AML
in vivo due to compensation by TNF-stimulated signaling.
Similar to TNF, IL1 stimulates the activation of
both JNK and NF-κB signaling [41]. Balanced JNK and
NF-κB signaling is critical for the proper response of
normal tissue cells to inflammatory cytokine-stimulated
reactions [42]. JNK induces pro-apoptotic activity in most
normal tissues, which causes tissue damage and even
tumor development when NF-κB signaling is inhibited.
However, in LCs, JNK mediates a proliferation/survival
signaling parallel to NF-κB signaling [16, 43]. Our study
suggested a mutual compensation of IL1 and TNF activity
in LCs by stimulating both JNK and NF-κB signaling.
Our studies suggested that combined inhibition of
JNK and NF-κB signaling might be a better treatment for
TNF and IL1-expressing M4/5 subtypes of AML [16].
Interestingly, we found that such combination treatment
was also effective in LCs isolated from patients with
therapy-related AMLs (Figure 8C). Such AMLs are less
responsive to any of the current therapies and portend
a poor prognosis. MLL rearrangements are commonly
detected in such AML samples [44]. It will be important to
determine whether JNK and NF-κB inhibitor combination
treatment can effectively repress therapy-related AML in
vivo. In addition, although our in vitro study suggested that
the TNF/IL1 low-expressing LCs are less responsive to
JNK and NF-κB inhibitor treatment, we predict that our
combined inhibitor treatment might also benefit these
AML patients when combined with standard therapies
because TNF and IL1 can be produced by bone marrow
niche cells during chemotherapy or radiation therapy. In
fact, accumulated data suggest that in AML patients, the
HSC-supporting niches are converted into inflammatory
leukemia-promoting niches [45]. Such an inflammatory
niche environment plays critical roles in leukemia drugresistance by protecting LSCs from chemotherapy [46,
47]. Whether or not TNF/IL1-induced JNK/NF-κB
signaling contributes to the development of drug resistance
needs to be further verified.
Multiple potential NF-κB inhibitors such as
the proteasome inhibitor bortezomib and the natural
compound parthenolide have been successfully used in
the clinical treatment setting for multiple myeloma and
are being evaluated in clinical trials for AML treatment in
combination with standard chemotherapeutic drugs [48,
49]. Unfortunately, clinical grade JNK inhibitors are not
available. We found that in these TNF/IL1-expressing AML
cells, as is the case with inactivation of JNK signaling,

DISCUSSION
The inflammatory reaction has been described as
a critical component of the tumor environment in many
solid tumors. In these tumor tissues, chemokines secreted
by malignant cells induce the infiltration of many types
of hematopoietic/immune cells (such as macrophages,
myeloid-derived suppressor cells, NK cells and T/Blymphocytes) to the tumor tissues. Most of the tumorinfiltrating hematopoietic/immune cells stimulate a
persistent cycle of damage and repair in tumor tissue to
generate a tumor-promoting inflammation by producing
tumor-supporting cytokines including TNF, IL1, and
IL6. Thus, such cells and the inflammatory cytokines
and signals generated by them have been proposed to be
critical targets for anti-tumor therapy [22–31]. However,
almost all of the previous studies evaluated anti-tumor
activity by targeting these cytokines and their signaling
pathways individually. In fact, signals stimulated by these
cytokines are not functionally independent. Most of these
cytokines share some common signaling pathways and
are functionally compensatory. Thus inactivation of one
cytokine-stimulated signal in most cases is insufficient to
repress tumor growth due to the compensation of signaling
stimulated by other cytokines. Our studies suggest that
removing at least TNF and IL1 is necessary to maximally
eliminate LCs, and especially for removing LSCs.
Consistent with earlier studies [32, 33], we found
that the expression of TNF and IL1 is elevated in many
subtypes of AMLs. The levels of TNF and IL1 are
increased and correlated to poor prognosis of AML
patients, especially older adults [5, 32, 33]. TNF is
primarily produced by LSCs/LPs and it promotes the
survival and proliferation of LSCs/LPs in an autocrine
fashion [11, 16], while IL1β is mainly produced by
LBs (Figure 3E, 3F), and also enhances the survival
and proliferation of LSCs/LPs in a dosage-dependent
paracrine manner. This might explain why cell density is
so important to detect the compensatory effect of IL1 on
TNF signaling inactivation.
An important role for IL1 in the pathogenesis of
AML has be proposed in early studies. It was demonstrated
that IL1 promotes the colony-forming ability of LCs by
stimulating the activation of downstream signaling and
the secretion of hematopoietic cytokines such as GM-CSF
in LCs and stromal cells [34]. IL1RAP, a well-known
co-receptor of IL1R, is highly expressed in many AML
patient samples and may be involved in LSC self-renewal
[35, 36]. In addition, elevated phospho-IRAK1, a hallmark
of activated IL1 signaling, is detected in advanced MDS
and AML patient samples, and has been suggested as
www.impactjournals.com/oncotarget
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inhibition of both IL1 and TNF represses growth and
significantly sensitizes clonogenic LPs and leukemogenic
LSCs to NF-κB inhibitor treatment. Given that both TNF
and IL1 antagonists are commonly used clinically to treat
rheumatoid arthritis and autoimmune diseases, and have
been confirmed to be safe, we speculate that we might able
to use these FDA-approved TNF/IL1 antagonists and NFκB inhibitors to evaluate our novel treatment approach in
AML patients. In addition, oral and intestinal mucositis are
severe pathologic conditions affecting most patients treated
with standard chemotherapy or radiation therapy [50–54].
TNF/IL1-mediated inflammation has been determined to be
responsible for such side effects.

LCs isolated from spleens and BM of the corresponding
leukemic mice were used in our studies.

Colony-forming unit assay
LCs and BM cells were seeded into MethoCult GF
M3434® (StemCell) at 1000 cells/mL (LCs) or 20,000
cells/mL (BM HSPC), incubated at 37oC, 100% humidity,
and 5% CO2 for 7 days (LC) or 10 days (HSPC cells).
Numbers of colonies were counted according to the
manufacturer’s instructions. Triplicate experiments were
performed in all of our studies. All data were verified
by three individual experiments. Primary AML patient
samples were seeded into MethoCult 4035 Optimum
without EPO and incubated at 37oC, 100% humidity, and
5% CO2. Colonies were read 14 days following seeding.

MATERIALS AND METHODS
Mice

Retroviral infection

The C57/Bl6J mice used as transplantation
recipients in this study were purchased from the Jackson
Laboratory and maintained in the Department of
Comparative Medicine, Loyola University Chicago. All
experiments using mice were performed according to the
guidelines of Loyola University Medical Center and were
approved by the Loyola University Institutional Animal
Care and Use Committee.

High-titer retrovirus was produced by cotransfecting Phoenix cells with a retroviral vector
containing the indicated genes together with packaging
vectors using Calphos Mammalian Transfection Kit
(Clontech). Retroviral supernatants were harvested 24
and 48 hours after transfection. MSCV-MLL-AF9-neo
was kindly provided by Nancy Zeleznik-Le of Loyola
University Chicago, and pMieg-DN-AP1 was obtained
from Addgene. Viruses were generated using these
retroviral vectors. LCs were transduced with such virusexpressing genes of interest by spinoculation at 32oC,
2000 rpm for 4 hours. Transduced cells were purified by
FACS for Western blotting and CFU assay.

Reagents
Recombinant murine-IL-3 (rm-IL-3), rm-IL-6, rm-SCF
and rm-GM-CSF were purchased from eBioscience (San
Diego). Recombinant human IL-3, IL-6, SCF, Flt-3, and TPO
were obtained from Humanzyme. TNFα was purchased from
BD Biosciences. BAY11-7085 and SP600125 small molecule
inhibitors were purchased from Millipore. Cell lysis buffer
(10×) was obtained from Cell Signaling, and supplemented
with proteinase inhibitors and phosphatase inhibitors (Roche
Diagnostics). GAPDH antibodies were obtained from Santa
Cruz Biotechnology. c-Jun, JunB, and JunD primary and
requisite secondary antibodies were also obtained from
Cell Signaling. Tri-reagent used for RNA extraction was
purchased from Sigma Aldrich. Etanercept® and Kinaret®
were graciously provided by the hematology/oncology clinic
at Loyola University Chicago. Methylcellulose for CFU
assays was purchased from StemCell Technologies. AntiCD11b and Anti-CD117 antibodies were purchased from
eBioscience. Wright-Geimsa solutions were purchased from
Exaxol (Clearwater, FL).

Ex vivo transplantation
Ten thousand LCs (CD45.2+) were plated in each
well in a suspension culture and treated with indicated
doses of BAY11-7085, SP600125, anti-TNF antibody
(Amgen), and IL-1Ra (Anakinra, Amgen) in indicated
combinations for 12 hours. All cells in each well were
harvested and mixed with 106 support BM cells (CD45.1+).
The mixed cells were equally divided and transplanted into
10 lethally-irradiated (350cGy) recipient mice (CD45.1+).
Mice were monitored for leukemia development by
observing for symptoms: hunched body, significant weight
loss, or hind-limb paralysis. Leukemia was confirmed by
examining CD45.2+ LCs in PB, spleen and BM, as well as
liver and kidney infiltration.

Generation of murine leukemia cell lines

In vivo transplantation and treatment

MLL-AF9 murine LCs were generated as previously
described [16]. Briefly, CD117+ HSPCs were isolated
from WT and Tnfr-/- mice (knockout of both Tnfr 1 and
2) and infected with MLL-AF9-neo-expressing retrovirus.
Infected cells were transplanted into lethally-irradiated
recipient mice to generate leukemic mice. WT and Tnfr-/-

Two thousand LCs were transplanted into sub-lethally
irradiated (350cGy) C57BL6/J mice via tail vein injection.
Twenty days after transplantation, mice were treated with
10mg/kg InVivoMAb anti m-TNFα (BioXcell), 10 mg/kg
BAY11-7085, 30 mg/kg SP600125, or IL-1RA (Anakinra,
Amgen) individually or in combinations every day for 10
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days. Mice were monitored for leukemia development by
observing for lethargy, paralysis, significant weight loss
and/or enlarged abdomen. Leukemia was verified after the
mice were sacrificed by examining for infiltration of LCs
into livers, lungs and spleens.

(BD Biosciences). Death of infected cells was examined
for the percentages of Annexin-V+ and AnnexinV+/7AAD+ cells by flow cytometry.

shRNA knockdown

One-way ANOVA with Bonferonni post-hoc test
was used for all in vitro comparisons, except where
otherwise noted. Log-rank test was used for all in vivo
comparisons. All statistical analyses were performed using
Graphpad Prism software.

Statistical analysis

LCs were transduced with retrovirus-expressing
shRNAs (Origene) specifically targeted to c-Jun
(TG501139), JunB (TG516091), JunD (TG501140), and IL1R (TG501076). The transduced cells were selected for one
week using puromycin (c-Jun shRNA) or by GFP sorting
(JunB, JunD, IL-1R) to obtain stably transduced cells.
Knockdown efficiency was examined by Western blotting
(c-Jun, JunB, JunD), or RT-PCR (IL-1R). Scrambled
shRNAs were transduced and studied in parallel as controls.
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